Are you delayed by data detours?

Try ta-Scan: the Reliable Road for Researchers

If finding clinical trial information is a trial itself, you’re using the wrong resource.
ta-Scan is an intelligence platform for clinical development, including:
•   Trial feasibility
•   Country allocation and site selection
•   Investigator profiles
•   Drugs and mechanisms of action linked to trials
•   Novel science and trends in disease management
•   Competing trials in your region

ta-Scan can facilitate:

Latest news

  • Get your FREE Immuno-Oncology Therapy Analysis by ta-Scan

    Today brings the start of the Immuno-Oncology Summit 2017 in Boston, supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers.

    MDCPartners and its ta-Scan team contribute to this purpose by teaching how clinical planners can leverage our clinical businesses intelligence software and our data merging services to get to their answers faster. The ta-Scan team created a useful analysis on oncolytic virus therapies in clinical trials. We thought today would be a good occasion to share this report with you.

    >>> Click here to download the analysis <<<

  • Connect with MDCPartners at the Immuno-Oncology Summit 2017

    Connect with MDCPartners at Immuno-Oncology Summit 2017 from August 28 to September 1, 2017 in Boston, MA. Visit MDCPartners at booth #32 to discover next generation targeted immunotherapies and find new ways to navigate clinical data and overlap internal data with MDCPartners’ public data cloud.

    Join us in Boston

    Would you like to know how our clinical business intelligence software ta-Scan or our other data solutions can help with your company’s data challenges? Then feel free to pop by booth #32 or make an appointment with MDCPartners’ Director of Business Development, North America Matt Tumasz and/or Strategic Analyst, Oncology, Dr. Jonathan Crowther. They will gladly show you our state of the art tools.

    Register Today

    Secure your place now if you want to connect with the ta-Scan team in Boston. MDCPartners has arranged for an exclusive discount on CHI’s Immuno-Oncology Summit. Use promo code MDC when registering to receive your $200 registration discount. This discount applies to conference programs only and cannot be used on short courses, combined with other offers, or transferred.

    How to register:
    Online: https://chidb.com/reg/imx/reg.asp
    By Phone: +1 781-972-5472

    Immuno-Oncology Summit 2017 Program

    Now in its fifth year, the Immuno-Oncology Summit will return to Boston again this August 28-September 1 with the goal of supporting researchers in developing the next generation of immunotherapies. Immuno-oncology researchers are changing the way we treat cancer by unleashing the immune system and achieving functional cures in some cancers.

    This year’s IO Summit has been designed to give attendees a complete picture of the field and its advances with 12 conference tracks, 1 in-depth training seminar, and 4 instructional short courses. Topics include immunotherapy discovery, development, biomarkers, and translational oncology as well as emerging topic areas such as cancer vaccines, oncolytic viruses, and advances in synthetic biology techniques. Overall, this event provides a focused look at how researchers are applying new science and technology in the development of effective and safe immunotherapies.

    Download the digital brochure for full details.

    We look forward to seeing you in Boston!

  • Meet David Cocker at DIA 2017 and discover the new ta-Scan mobile app!

    MDCPartners‘ CSO David Cocker will be attending the DIA 2017 meeting in Chicago on June 18-22 to showcase ta-Scan‘s new mobile app.

    About DIA 2017

    The Drug Information Association, a non-profit association, is the only global organization dedicated to bringing health care product development professionals together in a trusted, global, neutral environment to share insights and drive action in health care product development and life cycle management.

    ta-Scan Mobile App

    ta-Scan now has its own mobile app! Have a look at the video below: it’s a little demo on how it works. This tool enables MSLs to search for high ranking investigators on the go. Clinical business intelligence is now truly at your fingertips.

    Meet us in Chicago

    Book an appointment now to connect with David Cocker in Chicago.

    We look forward to seeing you in Chicago!

  • Curious about what to expect at ASCO 2017? ta-Scan has you covered!

    As ASCO 2017 kicks off this Friday, finding the information relevant to you can be a hassle. Using ta-Scan, you can quickly uncover key information about sponsors, clinical trials, drugs and investigators contributing to ASCO this year. To help you out, we highlight a few interesting points.

    asco 2017 abstracts

    Abstracts

    Over the past 3 years, there have been some notable changes in therapeutic areas discussed at the American Society of Clinical Oncology’s annual meeting. It comes as no surprise that the Immune Oncology trend is growing year on year, much like Lung Cancer. On the other hand, interest in Breast Cancer is steadily declining, which could be due to the disappointing results of Immune Oncology within Breast Cancer. Another interesting fact is the gain in Gastrointestinal Cancer abstracts at this year’s conference, after a relatively quiet 2016.

    asco 2017 abstracts ta distribution

    Sponsor & trial activity

    Of the 1,203 clinical trials that are cited at ASCO 2017, 6 key commercial sponsors have seen considerable fluctuations in trial activity when compared to ASCO 2016. Significant gains can be seen in the trial activity of BMS, Pfizer, and Roche, whereas Novartis, Sanofi, and Johnson & Johnson have seen a decrease in trial numbers.

    asco abstracts clinical trial activity

    ta-Scan’s top 5 drugs to watch at ASCO 2017

    With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

    Investigator & sponsor collaborations

    Looking at the percentage of top Oncology experts used by the leading commercial sponsors of trials talked about at ASCO 2017, it’s clear that Roche and Merck have an evenly distributed usage of investigators in both the USA as well as Europe, whereas others seem to lean toward USA investigator preference.

    asco 2017 abstracts top onco investigators

    ta-Scan’s top 5 drugs to watch at ASCO 2017

    With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

    asco 2017 abstracts new drugs

    Learn more about ta-Scan

    Interested in ta-Scan‘s analytical services? Request your free webinar here or contact us.

Publications / Downloads

  • Introduction to ta-Scan

    Get to know ta-Scan better with this general introduction fact sheet.

    US Letter Format | A4 Format
  • Clinical Trial Planning & Site Selection

    Learn how to use ta-Scan for clinical trial planning and site selection in this fact sheet.

    US Letter Format | A4 Format
  • Expert Profiling & Medical Affairs

    Learn how to use ta-Scan for expert profiling and medical affairs in this fact sheet.

    US Letter Format | A4 Format
  • Competitive Intelligence & Disease Landscapes

    Learn how to use ta-Scan for competitive intelligence and disease landscapes in this fact sheet.

    US Letter Format | A4 Format
  • Trial Feasibility Wizard

    Find out more information about ta-Scan's Trial Feasibility Wizard in this fact sheet.

    US Letter Format | A4 Format

Learn more about ta-Scan Book a webinar

Follow us on LinkedInMDCPartners

ta-Scan is a product of MDCPartners

MDCPartners specializes in business intelligence and strategic consultancy for clinical trial optimization and regulatory compliance. We combine our clinical development expertise with unique information technology and architecture to create innovative, cost-effective solutions for the pharmaceutical and medical device industry.

ta-Scan - Intelligence platform for clinical development

+32 3 870 97 50 |